Search for: "Takeda Pharmaceuticals International"
Results 41 - 60
of 69
Sorted by Relevance
|
Sort by Date
31 May 2011, 8:38 pm
General WIPO SCP16: Joint proposal of the African Group and the Development Agenda Group on a work program on Patents and Health (Knowledge Ecology International) Rogue pharmacies slide under Google radar (IP Osgoode) Australia slips further out-of-step on pharmaceutical extensions (Patentology) EU: Proposed EU Customs Regulation may not dispel fear of wrongful drug seizures (IP Watch) EU: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and… [read post]
25 Oct 2008, 12:03 am
Sandoz, Inc (Law360) (Hal Wegner) (Patently-O) (Patent Prospector) (PLI) Cipro (Ciprofloxacin) - US: CAFC finds no antitrust liability for Hatch-Waxman reverse payment settlements: In Re Ciproflaxacin Hydrochloride Antitrust Litigation (IP Law Observer) Lescol (Fluvastatin) - US: Mylan confirms first-to-file patent challenge to Lescol by Novartis (SmartBrief) Levaquin (Levofloxacin) - UK: Levofloxacin SPC valid: Generics (UK) Ltd v Daiichi Pharmaceutical Co Ltd & Anor (IPKat)… [read post]
21 Feb 2010, 4:17 am
.), also say any head-to-head trial where patients get Avandia and Takeda Pharmaceutical Co.'s diabetes medicine Actos would be "unethical and exploitative. [read post]
15 Apr 2010, 4:27 am
(EPLAW) Prevacid (Lansoprazole) – US: Takeda files patent infringement complaint against Zydus following Para IV challenge (Patent Docs) Reyataz (Atazanavir) – US: Bristol-Myer Squibb, Novartis file patent infringement suit against Teva following Para IV challenge (Patent Docs) Treximet (Sumatriptan, Naproxen) – US: POZEN enters into settlement agreement with Teva regarding Para IV patent litigation (SmartBrief) Zerit (Stavudine) – US: Promote Innovation files false… [read post]
19 Dec 2008, 1:00 pm
$16.8 million for Alphapharm and Mylan: Takeda v Mylan (Patent Baristas) (Patent Docs) Boniva (Ibandronic acid) – US: Apotex challenges validity of Hoffmann-La Roche’s Boniva patent (Law360) Boniva (Ibandronic acid) – US: Orchid Chemicals & Pharmaceuticals and Orgenus Pharma seek declaratory judgment of invalidity and noninfringement in patent infringement suit brought by Hoffmann-La Roche over Boniva (Law360) Cardizem (Diltiazem) –… [read post]
18 Mar 2010, 2:30 am
Mylan Pharmaceuticals, Inc. et al. [read post]
29 Apr 2016, 10:04 am
Takeda Pharmaceuticals, the makers of Actos, on the other hand, disagree with the link between their popular diabetes medication and bladder cancer and cite their own study data, which does not show such a causal link. [read post]
13 May 2010, 4:58 pm
Comptroller-General of Patents (EPLAW) (IP Factor) (SPC blog) Duetact (Pioglitazone and Glimepiride) – US: Infringement of patent following a Paragraph IV certification: Takeda Pharmaceutical Co. [read post]
9 Sep 2010, 7:09 pm
Zenith Goldline Pharmaceuticals, Inc., 471 F.3d 1369, 1377-79 (Fed. [read post]
30 Mar 2015, 12:18 pm
Takeda Pharmaceuticals North America, Inc., No. [read post]
3 Mar 2010, 5:05 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: Cozaar (Losartan), Hyzaar (Hydrochlorothiazide; Losartan) – US: Teva prevails in generic Cozaar/Hyzaar 180-day exclusivity forfeiture litigation: Teva v Kathleen Sebelius (FDA Law Blog) (SmartBrief) Nexavar (Sorafenib) - India: More on Bayer patent linkage - Supreme Court admits special leave petition filed by Bayer (Spicy… [read post]
3 Mar 2010, 5:05 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://duncanbucknell.com/subscribe/ Highlights this week included: Cozaar (Losartan), Hyzaar (Hydrochlorothiazide; Losartan) – US: Teva prevails in generic Cozaar/Hyzaar 180-day exclusivity forfeiture litigation: Teva v Kathleen Sebelius (FDA Law Blog) (SmartBrief) Nexavar (Sorafenib) - India: More on Bayer patent linkage - Supreme Court admits special leave petition filed by Bayer (Spicy… [read post]
14 Dec 2017, 10:48 pm
Actos diabetes drugs $2.4 billion In 2015, a federal judge in Louisiana reported that a Japanese drug company, Takeda Pharmaceutical, had agreed to pay $2.4 billion over claims that Takeda concealed the safety risks of its Actos diabetes drug before regulators warned that extended use could cause bladder cancer. [read post]
19 Mar 2015, 5:00 am
Takeda Takeda Pharmaceutical Co., 737 F.3d 116 (1st Cir. 2013), which dismissed similar allegations, but not on their (lack of) substantive merit.Briefly, in D’Agostino, the attack was on the “narrow” indication for which the defendant had obtained FDA approval of its product:In broad terms, [relator] alleges that [defendant] misled the FDA during the . [read post]
29 Apr 2010, 2:27 pm
The FDA has said it is undertaking an internal review of drug safety decision-making in addition to bringing Avandia to an advisory panel of outside experts in July. [read post]
14 Oct 2009, 7:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com] Highlights this week included: Angiomax (Bivalirudin) – US: Medicines Company files patent infringement suit against PLIVA, Barr, Teva following Para IV challenge (Patent Docs) (America-Israel Patent Law) (The IP Factor) (GenericsWeb) Humira (Adalimumab) – US: E D Texas find ‘close issue of claim construction’ supports JMOL of no… [read post]
2 Apr 2020, 6:30 am
Takeda Pharmaceutical Co. v. [read post]
27 Oct 2011, 4:24 am
The Actos plaintiffs allege that Takeda failed to warn about an increased risk of bladder cancer. [read post]
9 Mar 2012, 10:54 am
Pradaxa (dabigatran etexilate), manufactured by Boehringer Ingelheim Pharmaceuticals, was supposed to be one of those replacements. [read post]
24 May 2012, 4:23 am
We (and a whole bunch of other lawyers) assume that Takeda Pharmaceuticals will argue that the statute of limitations began to run on June 15, 2011, when the FDA issued an updated warning that one year of Actos use increases the risk of bladder cancer by more than 40%. [read post]
